Cardiovascular Systems enters Chinese market through OrbusNeich deal

Cardiovascular Systems (NSDQ:CSII) said today that it successfully launched its Diamondback 360 coronary orbital atherectomy system in China as part of a distribution agreement with OrbusNeich. St. Paul, Minn.-based Cardiovascular Systems said that the first patient has already been treated with the device in Hong Kong. “Orbital Atherectomy is simple to use. It is a very controllable and predictable atherectomy device and is especially useful for diffuse and severely calcified coronary arteries, ensuring the angioplasty procedures can be completed with ease and good results. OAS also helps to fill the gap of the conventional devices when treating calcified coronary arteries,” Dr. Michael Kang-Yin Lee of Hong Kong’s Queen Elizabeth Hospital said in a prepared release. Cardiovascular Systems said it originally inked the exclusive international distribution agreement with OrbusNeich in July this year, after having announced in January that it would serve as the exclusive U.S. distributor for OrbusNeich. “I was very pleased to have witnessed the first ever coronary orbital atherectomy procedure performed in Hong Kong. CSI’s device supports our key business focus of providing solutions for all complex vascular interventions. We look forward to continuing global distribution of this clinically proven technology to our customers,” OrbusNeich founder &chairman emeritus Teddy Chien said in a press release. “We are thrilled t...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Catheters Distribution Cardiovascular Systems Inc. OrbusNeich Source Type: news

Related Links:

Publication date: April 2019Source: Revista Española de Cardiología (English Edition), Volume 72, Issue 4Author(s): Juan Sanchis, Sergio García-Blas, Luis Ortega-Paz, Ana Paula Dantas, Enrique Rodríguez, Lidia Abellán, Salvatore Brugaletta, Ernesto Valero, Gema Miñana, Manuel Garabito, África Corchón, Julio Núñez, Arturo Carratalá, Manel SabatéAbstractIntroduction and objectivesCell-free DNA (cfDNA) in ST-segment elevation myocardial infarction might originate from hyperactivated leukocytes at the coronary lesion. Our aim was to investigate...
Source: Revista Espanola de Cardiologia - Category: Cardiology Source Type: research
To develop a clinically relevant model of percutaneous transluminal angioplasty (PTA) of venous stenosis in mice with arteriovenous fistula (AVF); to test the hypothesis that there is increased wall shear stress (WSS) after PTA; and to histologically characterize the vessels.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Laboratory Investigation Source Type: research
The risk of stent thrombosis (ST) or target lesion revascularization (TLR) is increased with smaller stent diameters (SD). Whether SD has a deleterious effect in women treated with early- vs. new-generation drug-eluting stents (DES) is unknown.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Short communication Source Type: research
It is unclear whether universal access to primary percutaneous coronary intervention (pPCI) may reduce sex differences in 1-year rehospitalization for heart failure (HF) and myocardial infarction (MI) after ST-elevation myocardial infarction (STEMI). We studied 7,597 consecutive STEMI patients (13.8% women, N=1,045) who underwent pPCI from January 2007 to December 2013. Cox regression models adjusted for competing risk from death were used to assess sex differences in rehospitalization for HF and MI within 1 year from discharge.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Limited data on sex differences by ethnicity following percutaneous coronary intervention (PCI) exist. In this prospective cohort study, we examined sex differences in 1-year outcomes among patients from 4 ethnic groups who underwent PCI from 2010-2016 at a tertiary center. The primary outcome was 1-year major adverse cardiovascular events (MACE) defined as composite of all-cause death, non-fatal myocardial infarction (MI), or target lesion revascularization (TLR).Secondary outcomes included composite of death or MI and individual components of MACE.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
There's a new surgical robot on the market in Europe and the Middle East, and this one can assist in stenting procedures such as angioplasty. Rouen, France-based Robocath developed R-One, which is the first European robotic solution to obtain the CE mark in the field of interventional cardiology. R-One is designed to enable precision technologies that complement existing methods, in order to improve procedures and the working environment. The company said the device uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. The R-One has an open architecture so it i...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news
(American College of Cardiology) Doctors can use either an artery in the arm (the radial approach) or in the groin (the femoral approach) to safely perform percutaneous coronary intervention (PCI) on patients presenting with a heart attack, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. The research, which was stopped early, suggests the radial and femoral approach are equivalent in terms of the risk of death at 30 days.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Coronary artery disease (CAD), a leading cause of mortality, affects patient health-related quality of life (HRQoL). Elective percutaneous coronary interventions (ePCIs) are usually performed to improve HRQoL ...
Source: BMC Medical Informatics and Decision Making - Category: Information Technology Authors: Tags: Research article Source Type: research
Coronary chronic total occlusion (CTO) is a common finding during coronary angiography and is associated with increased morbidity and mortality.1 Historically, treating a CTO with percutaneous coronary intervention (PCI) was technically difficult with a low success rate and a high rate of complications.1,2 Technical and operator skill advancements have led to an increased frequency and procedural success rate of contemporary CTO-PCI.3 Nevertheless, the benefit of this treatment remains controversial.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
This article reviews the latest data on unprotected left main (ULM) percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery, with a focus on the NOBLE and EXCEL trials.Recent FindingsIn EXCEL trial, the primary endpoint at 3  years was 15.4% in the PCI group and 14.7% in the CABG group (p = 0.02 for non-inferiority of PCI versus CABG). In NOBLE, the primary endpoint at 5 years was 28% and 18% for PCI and CABG, respectively (HR 1.51, CI 1.13–2.0, which did not meet the criteria for non-inferiority of PCI to CABG;p for superiority of CABG was 0.0044). Higher rep...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
More News: Angioplasty | Cardiology | Cardiovascular | China Health | Heart | Hong Kong Health | Hospitals | Profits and Losses | Training | Universities & Medical Training